Global biotherapeutics leader CSL Behring today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for etranacogene dezaparvovec (EtranaDez)...
Shanghai Henlius Biotech, Inc. announced that its first self-developed innovative PD-1 inhibitor HANSIZHUANG has been approved by the National Medical Products Administration (NMPA) for...
NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced it has received proceeds of approximately $4 million from the exercise...
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that NVX-CoV2373, its protein-based COVID-19 vaccine, is...
